Your browser doesn't support javascript.
loading
Autoantibodies neutralizing type I IFNs underlie severe tick-borne encephalitis in ∼10% of patients.
Gervais, Adrian; Marchal, Astrid; Fortova, Andrea; Berankova, Michaela; Krbkova, Lenka; Pychova, Martina; Salat, Jiri; Zhao, Shuxiang; Kerrouche, Nacim; Le Voyer, Tom; Stiasny, Karin; Raffl, Simon; Schieber Pachart, Anne; Fafi-Kremer, Samira; Gravier, Simon; Robbiani, Davide F; Abel, Laurent; MacDonald, Margaret R; Rice, Charles M; Weissmann, Gaia; Kamal Eldin, Tarek; Robatscher, Eva; Erne, Elke Maria; Pagani, Elisabetta; Borghesi, Alessandro; Puel, Anne; Bastard, Paul; Velay, Aurélie; Martinot, Martin; Hansmann, Yves; Aberle, Judith H; Ruzek, Daniel; Cobat, Aurélie; Zhang, Shen-Ying; Casanova, Jean-Laurent.
Affiliation
  • Gervais A; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.
  • Marchal A; Imagine Institute, Paris Cité University , Paris, France.
  • Fortova A; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.
  • Berankova M; Imagine Institute, Paris Cité University , Paris, France.
  • Krbkova L; Laboratory of Emerging Viral Diseases, Veterinary Research Institute, Brno, Czech Republic.
  • Pychova M; Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
  • Salat J; Institute of Parasitology, Biology Centre of the Czech Academy of Science , Ceské Budejovice, Czech Republic.
  • Zhao S; Laboratory of Emerging Viral Diseases, Veterinary Research Institute, Brno, Czech Republic.
  • Kerrouche N; Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
  • Le Voyer T; Institute of Parasitology, Biology Centre of the Czech Academy of Science , Ceské Budejovice, Czech Republic.
  • Stiasny K; Department of Children's Infectious Diseases, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Raffl S; Department of Infectious Diseases, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Schieber Pachart A; Laboratory of Emerging Viral Diseases, Veterinary Research Institute, Brno, Czech Republic.
  • Fafi-Kremer S; Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
  • Gravier S; Institute of Parasitology, Biology Centre of the Czech Academy of Science , Ceské Budejovice, Czech Republic.
  • Robbiani DF; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA.
  • Abel L; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA.
  • MacDonald MR; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.
  • Rice CM; Imagine Institute, Paris Cité University , Paris, France.
  • Weissmann G; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA.
  • Kamal Eldin T; Clinical Immunology Department, Assistance Publique Hôpitaux de Paris (AP-HP), Saint-Louis Hospital, Paris, France.
  • Robatscher E; Medical University of Vienna, Center for Virology , Vienna, Austria.
  • Erne EM; Medical University of Vienna, Center for Virology , Vienna, Austria.
  • Pagani E; Clinical Research Department, Hôpitaux Civils de Colmar, Colmar, France.
  • Borghesi A; Institut de Virologie, Strasbourg University Hospital, Strasbourg University, INSERM Unité Mixte de Recherche (UMR) S1109 , Strasbourg, France.
  • Puel A; Infectious Diseases Department, Hôpitaux Civils, Colmar, France.
  • Bastard P; Institute for Research in Biomedicine, Università della Svizzera italiana , Bellinzona, Switzerland.
  • Velay A; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.
  • Martinot M; Imagine Institute, Paris Cité University , Paris, France.
  • Hansmann Y; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA.
  • Aberle JH; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
  • Ruzek D; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
  • Cobat A; Department of Pediatrics and Neonatology, F. Tappeiner Hospital, Merano, Italy.
  • Zhang SY; Infectious Disease Unit, Provincial Hospital of Bolzano (SABES-ASDAA), Lehrkrankenhaus der Paracelsus Medizinischen Privatuniversität, Bolzano, Italy.
  • Casanova JL; Laboratory of Microbiology and Virology, SABES-ASDAA, Lehrkrankenhaus der Paracelsus Medizinischen Privatuniversität, Bolzano, Italy.
J Exp Med ; 221(10)2024 Oct 07.
Article in En | MEDLINE | ID: mdl-39316018
ABSTRACT
Tick-borne encephalitis (TBE) virus (TBEV) is transmitted to humans via tick bites. Infection is benign in >90% of the cases but can cause mild (<5%), moderate (<4%), or severe (<1%) encephalitis. We show here that ∼10% of patients hospitalized for severe TBE in cohorts from Austria, Czech Republic, and France carry auto-Abs neutralizing IFN-α2, -ß, and/or -ω at the onset of disease, contrasting with only ∼1% of patients with moderate and mild TBE. These auto-Abs were found in two of eight patients who died and none of 13 with silent infection. The odds ratios (OR) for severe TBE in individuals with these auto-Abs relative to those without them in the general population were 4.9 (95% CI 1.5-15.9, P < 0.0001) for the neutralization of only 100 pg/ml IFN-α2 and/or -ω, and 20.8 (95% CI 4.5-97.4, P < 0.0001) for the neutralization of 10 ng/ml IFN-α2 and -ω. Auto-Abs neutralizing type I IFNs accounted for ∼10% of severe TBE cases in these three European cohorts.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoantibodies / Interferon Type I / Encephalitis, Tick-Borne / Antibodies, Neutralizing Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: J Exp Med Year: 2024 Document type: Article Affiliation country: France Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoantibodies / Interferon Type I / Encephalitis, Tick-Borne / Antibodies, Neutralizing Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: J Exp Med Year: 2024 Document type: Article Affiliation country: France Country of publication: United States